GUCY1A1 Genotype

Your inherited DNA shapes how your blood vessels relax and how your platelets clot, and a single common variant in the GUCY1A1 (guanylate cyclase 1 soluble alpha 1) gene sits squarely at that intersection. This test reads your genotype at that location, giving you a one-time look at whether you carry the risk version of a gene tied to the nitric oxide signaling pathway that keeps arteries flexible.

Knowing this variant is most useful if you have a personal or family history of early heart artery disease, or if you are weighing decisions like daily aspirin where genotype may matter. The evidence here is still early, so this is best treated as one input into a broader picture rather than a standalone verdict.

What This Gene Actually Does

GUCY1A1 (and its close relative GUCY1A3, the older name used in much of the research literature) makes part of a protein called soluble guanylate cyclase. This protein is the main catcher for nitric oxide, the signal your body uses to relax blood vessel walls and quiet down platelets so they do not clump too eagerly. When this signal works well, arteries stay open and blood flows smoothly.

Variants in this gene can subtly change how strongly the pathway responds. That is why this gene shows up in research on coronary artery disease, stroke, and a rare brain blood vessel condition called moyamoya disease.

Coronary Artery Disease Risk

A case-control study of 232 people examined the GUCY1A1 variant rs7692387 in patients with unstable angina (a type of heart artery emergency where blood flow to the heart is suddenly restricted). Across the whole group, there was no statistically significant difference in how often the variant appeared in patients versus people without the condition. The headline finding: in this Polish population, the variant was not a major risk factor for unstable angina overall.

When the researchers split the group by age, they suggested the variant might raise risk in people younger than 55. That signal is exploratory and several of the comparisons did not reach statistical significance, so it should be read as a hypothesis rather than a settled finding.

A separate large analysis looking at genetic predisposition to enhanced nitric oxide signaling (the broader pathway this gene sits inside) studied 335,464 UK Biobank participants and linked stronger pathway signaling to reduced risks of coronary heart disease, peripheral arterial disease (clogged arteries in the legs), and stroke. That body of evidence supports the idea that the pathway matters for arteries, even where evidence on this specific variant in isolation remains thin.

Aspirin Response

A meta-analysis of two large aspirin trials (the Women's Genome Health Study and a case-control set from the Physician's Health Study) tested whether genotype at the GUCY1A3 risk locus changes how aspirin works for cardiovascular disease prevention. People who carried two copies of the risk allele (the G/G genotype) saw a reduction in cardiovascular risk when taking aspirin. Heterozygous carriers (one G and one A copy) saw the opposite pattern, with aspirin appearing to raise cardiovascular event risk in that group, along with higher bleeding risk. Bleeding risk on aspirin rose across all genotype groups, with the largest increase in heterozygotes.

This is one of the more interesting findings tied to this gene. It hints at why aspirin works well for some people and not others, and why a one-size-fits-all aspirin recommendation may quietly miss the mark. If you are considering aspirin for primary prevention, this genotype is a piece of information your standard lipid panel and blood pressure cuff cannot give you.

Moyamoya Disease

Rare loss-of-function mutations in the related gene GUCY1A3 have been linked to a subtype of moyamoya disease, a condition where brain arteries narrow and thicken in unusual patterns. In a study of three unrelated families, complete loss of soluble guanylate cyclase signaling led to severe moyamoya and early-onset achalasia (a swallowing disorder). A separate study of 255 Chinese patients with moyamoya found no disease-causing GUCY1A3 mutations in that population, where a different gene called RNF213 was the dominant driver.

This matters mainly for context: the rare severe mutations seen in moyamoya are biologically distinct from the common variant most pharmacogenetic panels are looking at. Carrying the common variant tested here does not mean you carry a moyamoya-causing mutation.

Why This Result Doesn't Change Over Time

Because this is a fixed germline genotype, your result is permanent. You inherited it from your parents, and it will read the same whether you test today, next year, or in twenty years. There is no version of "retest in 6 months to see if it changed."

What does need tracking is the downstream picture: standard lipid panels, ApoB (apolipoprotein B, a measure of artery-clogging particles), Lp(a) (lipoprotein little a, an inherited cardiovascular risk marker), blood pressure, and coronary artery calcium scoring if appropriate. Get a baseline of those markers if you haven't already, then repeat at least annually. The genotype tells you the inherited tilt of your risk. The phenotype markers tell you what your arteries are actually doing right now.

What an At-Risk Genotype Should Prompt You To Do

If you carry the risk variant, the most useful next steps are not about retesting your DNA, they are about going deeper on cardiovascular risk assessment and weighing intervention decisions more carefully.

• Get a full advanced lipid workup: ApoB and Lp(a) tell you more about your real artery risk than standard cholesterol alone, and the case for getting them done early is stronger if you carry a coronary artery disease risk variant.
• Consider coronary artery calcium scoring: a CT-based measurement of plaque buildup, this is the most direct way to see whether your inherited tilt has translated into real arterial damage.
• Have an informed aspirin conversation: if you are weighing daily aspirin for prevention, your genotype is part of the calculus. The trial evidence suggests the answer is not the same for everyone.
• Discuss with biological family: parents, siblings, and children may share the same variant. They do not all need to test, but the family conversation about early cardiovascular screening is worth having.

When Results Can Be Misleading

Genetic tests have their own set of confounders that differ from blood tests.

• Variant panel coverage: this assay reads specific positions in the GUCY1A1 gene. A result that does not flag a known risk variant does not rule out rare or undiscovered variants elsewhere in the same gene.
• Ethnicity matters: allele frequencies vary by ancestry. The risk implications studied in one population may not apply identically to another, and the moyamoya research makes this point clearly: the same gene drove disease in some populations but not others.
• Direct-to-consumer reports differ: if you have seen a 23andMe-style result that mentions this gene, the variants covered and the clinical interpretation may not match a clinical-grade panel.
• This is one piece of a polygenic story: coronary artery disease risk is shaped by hundreds of genes plus lifestyle. A single variant rarely tells the full inherited risk story on its own.

Honest Note on Clinical Maturity

This is a research-grade marker, not an established clinical test with standardized cutpoints and guideline-backed action thresholds. The strongest data are from the aspirin pharmacogenetic analysis and the broad nitric oxide pathway analysis. The evidence linking the specific common variant to incident disease in healthy adults is still thin. Treat your result as one signal among many, not as a verdict, and revisit the science periodically as it matures.